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Abstract
Background: Tuberculosis (TB) remains the most common cause of infectious disease deaths worldwide. What is
perhaps less appreciated is that the caseload of tuberculosis patients in South Asia is staggering.
South Asia has almost 40% of the global TB burden with 4,028,165 cases in 2015. This region also has a
disproportionate share of TB deaths (681,975 deaths, 38% of the global burden). Worldwide just 12.5% of TB cases
are in HIV positive individuals, but much research and investment has focused on HIV-associated TB. Only 3.5% of
patients with tuberculosis in South Asia have HIV co-infection. Not surprisingly with such a huge burden of disease,
this region has an estimated 184,336 multi drug resistant (MDR) cases among notified TB cases which accounts for
a third of global MDR burden. Crucially, at least 70% of the estimated MDR cases remain untreated in this region and
MDR treatment success ranged from only 46% for India to 88% for Sri Lanka in the 2012 cohort that received treatment.
This region represents many of the drivers of the modern TB epidemic: rapid urbanization and high density populations
with dramatically rising incidence of diabetes, a burgeoning and largely unregulated private sector with escalating drug
resistance and high air pollution both outdoor and household.
Conclusion: From bacterial biochemistry to policy implementation, we suggest ways in which South Asia can seize the
opportunity lead global TB elimination by demonstrating feasibility in some of the world’s most densely populated cities
and remotest reaches of the Himalayas. Clearly political will is essential, but we cannot defeat TB without understanding
how to eliminate it in South Asia.
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Background
Although tuberculosis (TB) remains the most common
cause of infectious disease deaths worldwide, impressive
gains have been made in TB control since the millen-
nium. Globally TB mortality fell by 47% between 1990
and 2015 [1]. Sixteen out of the 22 high TB burden
countries achieved the millennium development goals
for TB. The global health community has set a laudably
ambitious target for the post-2015 END-TB strategy of a
25% reduction in incidence and a 75% reduction in mor-
tality between 2015 and 2025, and by 2035 a 95% reduc-
tion in mortality and 90% reduction in incidence [1]. In
1967, when the decision was taken to push for smallpox
eradication, most believed it could not be done. There
were at that time 3 million deaths each year from small-
pox- a higher mortality than that of TB today. Although
TB elimination is a much more complex problem, our
understanding of infectious diseases, global connectivity
and range of interventions has also advanced. To accel-
erate TB elimination, we must maximize research in
high burden regions, and learn from failures to improve
translation, innovation and adoption to scale-up. South
Asia has the potential to act as a model region for TB
research and the drive towards elimination.
The caseload (Table 1, Fig. 1) of tuberculosis patients
in South Asia (India, Pakistan, Bangladesh, Bhutan, Sri
Lanka, Nepal, Afghanistan, Myanmar, and Maldives) is
staggering and not well appreciated [2]. South Asia has
almost 40% of the global TB burden with 4,028,165 cases
in 2015 [2]. This region also has a disproportionate share
of TB deaths (681,975 deaths, 38% of the global burden).
Worldwide just 12.5% of TB cases are in HIV positive
individuals, but much research and investment have
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focused on HIV-associated TB. Only 3.5% of patients
with tuberculosis in South Asia have HIV co-infection
(141,839/4,027190) [2]. This reflects the low prevalence
of HIV in the general population in South Asia, where
the epidemic is focused in high risk groups such as
intravenous drug users, commercial sex workers, men
who have sex with men and long distance truck drivers.
Population prevelance for young adults (15–49 years) in
the general population is below 1% for all countries, and
below 0.1% for four (Table 1). Not surprisingly with such
a huge burden of TB disease, this region has an esti-
mated 184,336 multi drug resistant (MDR) cases among
notified TB cases which accounts for a third of global
MDR burden [2]. Crucially, at least 70% of the estimated
MDR cases remain untreated in this region and MDR
treatment success ranged from only 46% for India to
88% for Sri Lanka in the 2012 cohort. This region repre-
sents many of the drivers of the modern TB epidemic:
rapid urbanization and high density populations with
dramatically rising incidence of diabetes [3, 4], a bur-
geoning and largely unregulated private sector and escal-
ating drug resistance. Factors affecting lung health and
therefore increasing susceptibility to TB are also of in-
creasing significance in South Asia: surging tobacco use
[3], occupational lung disease and high air pollution
both outdoor and household due to wood and dung as
cooking fuel [5, 6]. We cannot defeat TB without under-
standing how to eliminate it in South Asia.
Modelling studies suggest that even with full scale-up
of existing interventions using unlimited resources, the
END TB targets are not achievable in India; the chal-
lenges in other countries in the region are even greater
Table 1 Tuberculosis in South Asia in 2015
Country TB Incidence
(per 100,000
population)
Absolute number of
new TB cases 2015 (N %)
HIV prevalence
general populationa
Absolute number of TB
cases in HIV infected
individuals 2015
Absolute number of
MDR TB cases 2015
Absolute number of
deaths from TB 2015
Afghanistan 189 61,000 (1.5) < 0.1 460 (0.3) 3000 (1.63) 12,170 (1.8)
Bangladesh 225 362,000 (9.0) < 0.1 630 (0.4) 9700 (5.3) 73,230 (10.7)
Bhutan 155 975 (0.02) No estimate 6 (0.004) 37 (2.0) 144 (0.02)
India 217 2,840,000 (70.5) 0.3 113,000 (79.7) 130,000 (70.5) 517,000 (75.8)
Nepal 156 44,000 (1.1) 0.2 1900 (1.3) 1500 (0.8) 1900 (0.3)
Maldives 53 190 (0.004) No estimate 0 (0) 10 (0.005) 20 (0.003)
Myanmar 365 197,000 (4.9) 0.8 17,000 (12.0) 14,000 (7.6) 27,000 (4.0)
Pakistan 270 510,000 (12.7) 0.1 8800 (6.2) 26,000 (14.1) 45,600 (6.7)
Sri Lanka 65 13,000 (0.3) < 0.1 43 (0.03) 89 (0.05) 1211 (0.2)
South Asia Total 4,028,165 (100) 141,839 (100) 184,336 (100) 681,975 (100)
aAdults aged 15–49. Source UNAIDS data. Available at: http://aidsinfo.unaids.org/
Fig. 1 Tuberculosis in South Asia
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[7]. There is often a substantial gap between policy and
practical implementation [8]. These studies underline
the need to improve our fundamental armoury in the
fight for TB elimination through strengthened and sus-
tained research capacity in high burden countries.
South Asia was a key player in the early clinical trials
optimizing TB case management, including the famous
‘Madras’ study [9]. The last decade has again seen many
notable contributions to TB control from South Asia,
there is a clear opportunity to build on these achieve-
ments. Only by investing in, scaling up and strategically
networking our research efforts in South Asia we can
optimize effective multifaceted interventions to achieve
TB elimination in Asia.
The zero TB cities initiative in Chennai represents one
example of innovative multifaceted research in the region.
By investing in strategically planned research and imple-
mentation now, we can seize the tide and advance the
tools we need to achieve the ambitious targets we have set
ourselves. From active case finding, diagnosis and treat-
ment to bacterial biochemistry to research priorities and
policy implementation, in this presentation, we suggest
ways in which South Asia can seize the opportunity to
help in leading global TB elimination by demonstrating
feasibility in some of the world’s most densely populated
cities and remotest reaches of the Himalayas.
Diagnosis and active case finding
The 2016 WHO global TB report has substantially re-
vised estimates of TB burden in India upwards [2]. Evi-
dence was collated from a number of sources, including
a statewide prevalence survey in the relatively wealthy
state of Gujarat which showed prevalence of TB 50%
higher than previously estimated. This means in turn
that case notification is substantially lower than previ-
ously estimated, revised downwards to 59% rather than
74% [2]. It is likely that prevalence surveys in other
countries of the region, including the one just launched
in Nepal, will find similar underestimates of burden. The
keystone of epidemic control for infectious diseases,
from smallpox to SARS and ebola, has always been case
identification and interruption of transmission. While
the roll-out of the molecular GeneXpert test has im-
proved TB diagnosis and it is hoped it will reduce the
diagnostic gap, population coverage remains low in
South Asia [10]. Table 2 summarises the availability of
GeneXpert in 2016 South Asian countries. As of 31st
December 2016, the region averaged 0.28 GeneXpert
modules procured per 100,000 population. The availabil-
ity GeneXpert modules are generally concentrated in
large urban centres and average data masks regional
variability and further overestimates coverage due to is-
sues with maintenance of installed modules. Despite the
huge burden of tuberculosis in this region and national
policies which often include contact tracing, in routine
practice there has been an almost exclusive focus on
passive case finding, with diagnosis and treatment of
only the index patient [11]. Due to resource constraints,
there has been until recently very little emphasis on ac-
tive case finding (screening individuals at increased risk
of the disease) in susceptible populations such as house-
hold contacts of patients with tuberculosis or in areas of
highest transmission (for example cities in South Asia
[12, 13]) so that treatment can be begun and the patient
rendered non- infectious [14]. While this is now widely
recognized as a major gap in TB control activities, short
term ‘demonstration’ projects or pockets of intensified
activity must translate to sustained comprehensive na-
tional active case finding integration to national TB pro-
grammes [11]. Innovative public-private engagement in
Pakistan funded initially by TB REACH has recently
been awarded over 40 million USD from the Global
Fund to scale up nationwide and integrate it within na-
tional TB control activities [15]. The next step is to
Table 2 GeneXpert availability in countries of South Asia as of 31st December 2016(http://apps.who.int/tb/laboratory/xpertmap/)
Country No of Xpert modules
procured
Total population
(thousands, 2016)a
Modules per 100, 000
population
No. of Xpert cartridges
procured
Afghanistan 42 34,656.03 0.12 10,770
Bangladesh 424 162,951.56 0.26 381,210
Bhutan 12 797.76 1.23 2600
India 3000 1,324,171.35 0.23 2,134,760
Maldives 4 417.49 0.96 500
Myanmar 416 52,885.22 0.79 340,370
Nepal 143 28,982.77 0.49 136,170
Pakistan 1012 193,203.48 0.52 525,500
Sri Lanka 62 21,203.00 0.29 13,100
Total 5115 1,819,268.66 0.28 n/a
aSource: UN population division: https://esa.un.org/unpd/wpp/
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adapt such successful projects to other countries in the
region for evaluation and scale-up.
South Asia has a massive, confusing and unregulated
private health sector. The vast majority of hospitals in the
region are privately run with a great mix of alternative dis-
ciplines like homeopathy, Tibetan and Ayurveda. Pakistan,
for example, has a very rich tradition in the use of medi-
cinal plants for the treatment of various ailments based
predominantly on the Unani system of medicine, which
dates back to the Indus valley civilization [16]. Private
practitioners often begin the initial management of tuber-
culosis, with increasing evidence that the role of the pri-
vate sector is larger than previously suspected.
Mandatory case notification and national web-based
reporting introduced in India in 2012 generated a 34%
in annual case notifications in 2015 compared to 2013.
This system should be replicated regionally. India,
Bangladesh and Pakistan are three out of the ten coun-
tries globally with the biggest gap between TB notifica-
tion and estimated incidence.
In addition to missed opportunities for case notifica-
tion, a largely unregulated private sector has led to wide-
spread misdiagnosis and treatment of TB cases. The
consequences for individual patients are severe, both in
terms of increased morbidity and financial burden. From
a wider public health perspective, this leads to gener-
ation and propagation of drug resistant strains of TB.
The first report of totally drug resistant TB came from
India in 2012 [17]. Although this term is not recognized
by the World Health Organization due to difficulties of
definition [18], the report reflects South Asia as an incu-
bator for drug resistant forms of TB with an ever in-
creasing spectrum of resistance.
Poor access to TB diagnostic services, which can be
caused by many factors including financial barriers,
transport, clinic opening hours and stigma, led to the
widespread use of inaccurate commercial serological
diagnostic tests for TB. Despite their lack of accuracy,
these tests offer simple, rapid and economical ‘TB test-
ing’ at pharmacies or cornershops. In many cases equiva-
lent as a diagnostic aid to tossing a coin, use of these
tests results in both delayed diagnosis for TB cases and
overtreatment of individuals not having TB [19–21]. In
2011 WHO issued an unprecedented negative advisory
on the use of such tests and the Indian government
responded by banning the tests [22]. In reality, they re-
main widely available and continue to be aggressively
marketed by companies. This landmark ban should be
implemented region-wide and companies marketing un-
approved tests for TB should be penalized to discourage
the practice.
However, development and evaluation of novel diag-
nostic tests should not be discouraged. Commercial de-
velopment of TB tests often suffers from lack of access
to sputum from patients early in the development
process. Prototype tests can consequently be manufac-
tured for clinical evaluation which are unsuitable for use
with real sputum or insufficiently sensitive to detect low
numbers of bacilli after sputum processing. The high
volume of potential TB patients screened in large clinics
in South Asia provides an opportunity for the establish-
ment of early diagnostic development centres, where
prototype tests can undergo rapid early evaluation and
feedback following standardized protocols. Such a diag-
nostic evaluation centre would reduce delays in obtain-
ing ethical approval by having pre-approval to evaluate
novel tests requiring only residual sputum samples and a
rapid review process and standard commercial partner-
ship agreement for each novel test requesting evaluation.
Treatment
The patient burden in South Asia makes it ideally suited
for the large scale clinical trials needed to evaluate TB
regimens. Clear regulatory frameworks and procedures
to obtain ethical consent can encourage clinical trials
within countries while maintaining rigorous ethical stan-
dards [23]. The complexity of the clinical trials approval
process in India has discouraged inclusion in multi-
country trial networks. Recent changes have caused frus-
tration but are an attempt to improve transparency [23].
By developing clear, transparent national guidelines to
help academics and commercial organisations navigate
the process and anticipate timeframes for approval, the
number of clinical trials funded can be greatly increased.
The recent licensing of bedaquiline and delamanid is a
major advance in our fight against drug resistant TB [24,
25]. However, licensing single drugs and allowing either
unregulated use or reserving them for patients with the
broadest resistance spectrums will foster the rapid emer-
gence of resistance to our last line of defence. Balancing
the needs of pharmaceutical companies to generate
profits and the need for compassionate use of novel
drugs in patients with no other options with the optimal
public health strategies for protecting susceptibility to
the drug is always a delicate balancing game. Govern-
ments and international agencies need to explore novel
guarantees and incentives for pharmaceutical agencies,
along the lines of the guaranteed ‘buy-down’ offered by
UNITAID which facilitated the rapid roll-out of GeneX-
pert MTB/RIF. Attention is beginning to focus on the
need for novel regimens rather than agents but may be
too late as bedaquiline becomes more widely available.
The Nix-TB trial has reported encouraging early results
for a novel 3-drug regimen. Over the last 50 years we
have actually preserved susceptibility to the limited
number of potent antituberculous agents available re-
markably well. This is largely due to the very early adop-
tion of multi-drug therapy. By ‘locking’ new drugs into
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fixed dose combinations at the outset, we may more ef-
fectively preserve their utility. Structured rotation of first
line regimens, as modelling studies have suggested as a
strategy for malaria, may be another effective approach
for the region, but will depend on the licensing of fur-
ther novel agents [26].
In South Asia, pharmacies play a major role in the
treatment of infectious diseases including TB with over-
the- counter sale of many antibiotics with a very poor
referral tradition even when the patient presents with
classical symptoms of TB. In a recent study from India,
only 13% of 599 pharmacies studied in Mumbai, Patna
and Delhi refrained from selling antibiotics or steroids
and properly referring a patient with two to 3 weeks of
pulmonary TB symptoms [27]. Rules are in place but
seldom followed. This behavior is characteristic of other
countries such as Nepal and Bangladesh in this region.
In another recent surprising finding from India, it has
been shown that about two thirds of TB treatment may
be handled by the private sector [28]. Although tubercu-
losis is a notifiable disease in many countries in South
Asia including India, private practitioners are averse to
notify [29] and there is no penalty involved. Worryingly,
a study conducted in Dharavi, Asia’s most densely popu-
lated slum in the heart of Mumbai, India showed only
3% of the doctors practicing there were able to provide a
correct prescription for a patient with MDR TB [28, 30].
Effective treatment depends on accurate diagnosis of
drug resistance [31]. The GeneXpert scale-up has dra-
matically increased detection of MDR TB in the region.
An 18 site Xpert implementation study demonstrated a
5-fold increase in resistant TB detection region [32].
The new, smaller more portable point of care Gene
Xpert Omni scheduled for release in 2017, with a built
in 4 h battery can potentially be used even in the far-
flung regions of the Himalayas, Hindu Kush and Kara-
koram to improve confirmed diagnosis of TB and reduce
unnecessary treatment. Until molecular drug susceptibil-
ity testing for drugs other than rifampicin improves,
phenotypic drug susceptibility testing will remain neces-
sary to appropriately treat MDR TB cases. Despite the
population of 1.8 billion, the ratio of Drug Sensitivity
Testing (DST) laboratories to population remains abys-
mally low at about 0.2 labs per 5 million population.
Scale-up of quality-assured laboratory capacity is an es-
sential component of any realistic attempt to combat
drug-resistant TB in the region. It is hoped that im-
proved methods for rapid whole-genome sequencing of
tuberculosis deployable in resource limited settings may
‘leapfrog’ the need for substantial scale-up of phenotypic
DST in the next decade (http://www.crypticproject.org/).
It is estimated that around 500 drug susceptible pa-
tients can be treated for the same cost as a single MDR
case. Investing in strong MDR TB control is therefore
highly cost effective if it successfully averts MDR trans-
mission. In addition, the new shorter MDR TB treat-
ment regimen from Bangladesh now recommended by
the WHO should be implemented regionwide [33].
Strategies to improve TB patient outcomes must in-
clude evaluation of policies to facilitate adherence to
treatment and improve outcomes. The application of
mobile technologies to healthcare (M-health) has the po-
tential for a transformational role in TB case manage-
ment and reducing loss to follow up. Observation of
treatment by video adherence (V-DOTS) can improve
decentralization of treatment services and increase ad-
herence. The role of M-health is under-explored in TB
management [34].
TB is a disease entwined with poverty, and cata-
strophic household costs incurred by TB patients have
been shown to be as significant a risk factor for default
from treatment as MDR TB. Efforts are currently under-
way to map patient costs at national level led by WHO.
The household burden and long-term repercussions can
be alleviated by policies such as microcredit and cash
transfer and optimal strategies need to be evaluated for
scale-up in South Asia [35]. South Asia with rapid eco-
nomic change has the potential to be at the forefront of
interventions to eliminate catastrophic costs for TB [1].
Prevention and infection control
The huge reservoir of latently infected individuals glo-
bally presents a substantial challenge to eradication ef-
forts. Modelling of control strategies has consistently
revealed that without tackling latent TB, eradication will
not be feasible. For decades an unsubstantiated figure of
‘one third of the world’s population’ has been quoted as
the number of people with latent TB, but a recently pub-
lished study using annual risk of infection estimates de-
rived from a number of sources produced a figure of 1.7
billion people, a quarter of the world population [36].
Scaling up isoniazid preventative therapy (IPT) in en-
demic countries has only received serious consideration
in the last decade. For large scale IPT to be feasible,
shorter regimens must be developed as well as regimens
applicable in areas of high isoniazid resistance. The 12-
dose, 3 month, rifapentine-isonaizid regimen is a step in
the right direction but more must be done to evaluate
strategies for IPT scale up beyond those currently being
undertaken in people living with HIV. The interferon-
gamma release assays (IGRA) tests for latent TB infec-
tion are impractical for large scale screening and do not
predict those at greatest risk of developing active TB.
Strategies for targeted prophylaxis need to be included in
packaged interventions applicable to both urban and rural
Asia [37]. Similarly, simple inexpensive infection control
measures in healthcare settings including administrative
changes, opening windows to improve ventilation or
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Table 3 Research priorities for TB in South Asia
Theme Priority Research areas AIMS
Diagnosis
Engaging the public sector to capture notifications and ensure
treatment quality
Understanding components of successful Public Private Mix(PPM)
models and resources needed for national scale-up
Optimal algorithms and implementation behaviour Improving application of optimal diagnostic algorithms.
Facilitators and barriers to diagnostic access Removing access barriers for TB diagnosis in underserved populations
Childhood TB Access to TB diagnosis for all children at risk
Targeting Active Case Finding (ACF) Understanding how to target ACF activities to maximise yield for
minimal resources.
Mobile health applications for TB Minimising loss to follow up in diagnostic pathway and maximising
outreach of novel diagnostics. Eg. Remote Chest Xray reading.
Scale up of Drug Susceptibility Testing(DST) availability Increasing access to full drug susceptibility testing through molecular
scale-up and improving culture facilities in underserved populations.
Integrating TB and diabetes Understanding risk factors for TB among diabetic patients and
optimal implementation of TB screening.
Treatment
Increasing Randomized Controlled Trial (RCT) capacity Develop regional network and ability to systematically evaluate
multiple regimens in adequately powered trials.
Treatment of drug resistant TB, including INH mono-resistance,
Multidrug Resistance(MDR) and Extensively Drug Resistance (XDR) TB.
Programme of trials to systematically answer locally relevant questions,
including both alternative regimens and treatment delivery strategies
Theoretical and practical studies to understand consequences of
different approaches to novel drug roll-out
Optimising novel drug implementation in terms of negative
outcomes averted and preventing emergence of resistance.
Increasing drug resistance surveillance Evaluating strategies applying molecular technology to increase
monitoring of drug resistance prevalence and emergence
Systematic evaluation of variation in pharmacokinetics and
pharmacodynamics
Dose optimisation for existing drugs in adults and children to
maximise efficacy, minimise adverse events and prevent resistance.
Adverse drug events Understanding susceptibility risk, improved detection and management
of Adverse Events (AEs) and development of personalised regimens to
avoid AEs.
Retreatment regimen in non-MDR cases Retreatment regimens that are economically feasible and effective
allowing abolition of the currently failing ‘category 2’ retreatment
regimen.
Mobile health for Video Directly Observed Therapy (V-DOTS) and
adherence
Alternative strategies for treatment monitoring to increase compliance
while minimising costs and disruption to the patient.
Optimal treatment of TB in diabetic patients. Evidence base for optimal treatment and case management of TB
in diabetic patients.
Prevention
Correlates of immunity Understanding of components of a protective immune response for
vaccine development.
Standardising implementation of basic infection control in health
care facilities regionwide
Development of evidence- based recommendations for minimal
infection control standards in regional health care facilities.
Targeted prophylactic therapy Evidence base for risk:benefit of scale-up of prophylactic treatment
in different population groups.
Strengthening health systems resilience Contingency measures for natural or political upheavals leading to
person displacement or infrastructure loss
Heterogeneity of risk in populations Understanding molecular epidemiology of TB susceptibility and
transmission in both dispersed rural and high density urban
populations. Optimal targeting of TB control activities to appropriate
risk groups.
Risk of active TB in latently infected individuals Biomarkers and social factors influencing risk for latently infected
individuals developing active TB to optimise targeted prophylaxis.
Host:pathogen interaction in susceptibility and transmission Integrated analysis of host and pathogen genomes to understand
complex interplay of host susceptibility and pathogen virulence.
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conducting question based screening of hospital attendees
can protect healthcare workers and vulnerable patients
from infection [38]. Such measures are not generally ap-
plied in South Asia and should be scaled up systematically
through healthcare facilities in the region.
South Asia also has high vulnerability to natural disas-
ters and political disruption. Contingency measures can
go far in reducing the opportunistic spread of disease
such as TB when disaster inevitably strikes. In the after-
math of the 2015 earthquake in Nepal, although funding
was available a lack of capacity for delivery meant that
suggested [39] simple healthcare measures were not de-
livered. Displaced people living in temporary, over-
crowded shelters with no sanitation made millions of
Nepalis vulnerable to infectious disease transmission, in-
cluding TB and MDR TB. Damaged DOTS clinics and
loss of drugs led to treatment interruptions for hundreds
of TB patients.
Research priorities
It is unlikely we will have an effective vaccine for TB
within the next decade [40]. While we should not neg-
lect vaccine research, we must make plans to advance
towards TB eradication without a vaccine, rather than
waiting for the ‘holy grails’ of a perfect vaccine or a sub-
stantially shortened regimen. South Asia is ideally and
uniquely placed to contribute much needed strategic evi-
dence towards the global eradication campaign.
Research priorities (Table 3) for the region must focus
on packaged interventions both in large urban cities and
remote rural populations. Alongside operational research
to understand and optimize packaged interventions in-
cluding patient incentives and social support, manage-
ment and logistical strengthening and policy frameworks,
early stage research should include robust diagnostic
evaluation centres for early stage diagnostic development
to complement the pipeline of demonstration/evaluation
studies with FIND, an organization which works to im-
prove the diagnosis of tuberculosis. Research capacity
should be strengthened by enlarging the network of good
clinical practice (GCP) compliant clinical trial sites to
speed up novel regimen evaluations, improving laboratory
capacity for bacterial culture and drug susceptibility
testing, strengthening ‘omics capacity to understand sus-
ceptibility, transmission and drug resistance emergence.
Networking research across the region to share and scale-
up best practice, engaging governments and funders in
the research agenda to ensure translation and political
commitment to sustainable funding.
Conclusion
There is a clear opportunity as development in South
Asia surges ahead to harness the power of the region’s
skilled scientists and develop a regional research agenda
for TB which encompasses the many facets of this com-
plex problem. From bacterial biochemistry to policy im-
plementation, South Asia has the patient numbers
combined with a rich pool of innovative scientists which
could enable it to seize the opportunity and lead global
TB elimination by demonstrating feasibility in some of
the world’s most densely populated cities and remotest
reaches of the Himalayas. Clearly, political will and vi-
sionary leadership is of paramount importance, but TB
will not be defeated by a single intervention and innova-
tive measures will be essential. The time is ripe for re-
searchers in the region to network together, develop a
unified agenda and ensure successful research has a clear
pathway to scale-up and impact towards TB eradication
by 2050.
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